ReachMD CME

By ReachMD

What's ReachMD CME about?

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Download our free app to listen on your phone

ReachMD CME episodes:

04.23.2024
Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-the-treatment-of-attrv-pn-whats-in-the-pipeline/24139/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
ATTRv-PN: A Family Affair?
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/attrv-pn-a-family-affair/24138/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
Shh…Gene-Silencing Therapies for ATTRv-PN
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/shhgene-silencing-therapies-for-attrv-pn/24137/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
Diagnosing ATTRv-PN: What's in Your Toolbox?
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-attrv-pn-whats-in-your-toolbox/24136/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/raising-the-red-flag-whats-your-index-of-suspicion-for-attrv-pn/24135/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
The Multiple Faces of ATTRv-PN
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-multiple-faces-of-attrv-pn/24134/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
ATTRv-PN: A Complicated Disease With a Poor Prognosis
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/attrv-pn-a-complicated-disease-with-a-poor-prognosis/24133/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.23.2024
ATTR Amyloidosis: Familial Vs Wild-Type
CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/attr-amyloidosis-familial-vs-wild-type/24132/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore...
04.15.2024
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME credits: 0.50 Valid until: 15-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/gprc5d-targeted-bispecifics-in-relapsedrefractory-multiple-myeloma-practical-expert-consensus-on-a-new-target-with-unique-adverse-events/24141/ GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of...
$GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events$
04.15.2024
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
CME credits: 0.25 Valid until: 15-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/making-the-case-for-dual-ang-2-vegf-a-inhibition-durability-and-drying/18008/ What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as...
04.15.2024
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
CME credits: 0.25 Valid until: 15-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/ There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities...
04.11.2024
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
CME credits: 1.00 Valid until: 02-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/get-real-a-guide-to-evolving-treatment-of-namd-and-dme-using-real-world-data/16619/ Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced...
04.09.2024
South Asians With IBD: Underrepresented and Underappreciated
CME credits: 0.25 Valid until: 16-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/south-asians-with-ibd-underrepresented-and-underappreciated/18122/ A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the...
03.29.2024
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-effectively-integrate-the-latest-vte-treatment-and-secondary-prevention-guidelines-into-clinical-practice/24238/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/mrs-vt-elizabeth-a-case-study-on-the-secondary-prevention-of-vte/24237/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/vte-prophylaxis-in-patients-at-risk-for-a-secondary-vte-event-options/24236/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-whos-most-susceptible-for-a-secondary-vte-event/24235/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Patient With VTE
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/putting-it-all-together-coordinating-the-multidisciplinary-care-plan-for-the-patient-with-vte/24234/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Case Time! VTE Prophylaxis Post Hip Replacement
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-time-vte-prophylaxis-post-hip-replacement/24233/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Right from the Onset: PE Diagnosis, Management
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/right-from-the-onset-pe-diagnosis-management/24232/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Right from the Onset: DVT Diagnosis, Management
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/right-from-the-onset-dvt-diagnosis-management/24231/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
What Do the Guidelines Suggest for Prophylaxis, and How Do We Implement?
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-do-the-guidelines-suggest-for-prophylaxis-and-how-do-we-implement/24230/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
Case Time! V.T. Edwards: Management of Extended Thromboprophylaxis in the Medically Ill
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-time-vt-edwards-management-of-extended-thromboprophylaxis-in-the-medically-ill/24229/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-options-are-available-prophylactically-for-my-acute-and-post-acute-medically-ill-patients/24228/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?
CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-acute-and-post-acute-risk-of-vte-in-acute-medically-ill-patients/24227/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at...
03.29.2024
From Awareness to Action: What To Do With a Positive OSA Screen?
CME credits: 0.50 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/from-awareness-to-action-what-to-do-with-a-positive-osa-screen/24194/ One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your...
03.29.2024
How to Screen for OSA
CME credits: 0.50 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-to-screen-for-osa/24193/ One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your...
03.29.2024
Overcoming Hurdles: Effective OSA Screening in Primary Care
CME credits: 0.50 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-hurdles-effective-osa-screening-in-primary-care/24192/ One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your...
03.29.2024
Pre-Operative Vigilance: The Role of OSA Screening in Surgical Safety
CME credits: 0.50 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/pre-operative-vigilance-the-role-of-osa-screening-in-surgical-safety/24191/ One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your...
03.29.2024
OSA: Exploring the Impact on Morbidity and Mortality
CME credits: 0.50 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/osa-exploring-the-impact-on-morbidity-and-mortality/24190/ One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your...
03.29.2024
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME credits: 0.25 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/applying-sdm-to-personalize-treatment-discussions-on-recurrence-risk-reduction-in-patients-with-early-stage-melanoma/18105/ This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to...
03.25.2024
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
CME credits: 0.50 Valid until: 25-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/ The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF)...
03.22.2024
Collaboration and Management of HE: Establishing Foundation for Successful Outcomes
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/collaboration-and-management-of-he-establishing-foundation-for-successful-outcomes/24185/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
HEar My Needs: Enhancing the Patient and Provider Dialogue
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/hear-my-needs-enhancing-the-patient-and-provider-dialogue/24184/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
Equitable HEalth for All: Improving Care for Underserved Populations and Their Unmet Needs
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/equitable-health-for-all-improving-care-for-underserved-populations-and-their-unmet-needs/24183/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
How Do I Prevent Future Hospital Visits due to HE?
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-do-i-prevent-future-hospital-visits-due-to-he/24182/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
The Unmet Need for HE Therapy in the African American Community – Why Is This a Concern?
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-unmet-need-for-he-therapy-in-the-african-american-community-why-is-this-a-concern/24181/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
HElp! AASLD Guidelines Related to Diagnosis of HE
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/help-aasld-guidelines-related-to-diagnosis-of-he/24180/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
West HavEn Criteria—Meaningfulness Into Clinical Practice
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/west-haven-criteriameaningfulness-into-clinical-practice/24179/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
Tackling the Unmet Need HEad On—What Does HE Look Like?
CME credits: 1.25 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/tackling-the-unmet-need-head-onwhat-does-he-look-like/24178/ Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease....
03.22.2024
Emerging Therapeutics in ADH1: Progress in Precision Medicine
CME credits: 1.00 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutics-in-adh1-progress-in-precision-medicine/24177/ Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low...
03.22.2024
Therapeutic Options for ADH1 and Hypoparathyroidism
CME credits: 1.00 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-options-for-adh1-and-hypoparathyroidism/24176/ Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low...
03.22.2024
CASR and ADH1: Integrating Biology and Genetic Screening
CME credits: 1.00 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/casr-and-adh1-integrating-biology-and-genetic-screening/24175/ Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low...
03.22.2024
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
CME credits: 1.00 Valid until: 22-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/increasing-adh1-awareness-a-hidden-cause-of-hypoparathyroidism/24174/ Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low...
03.20.2024
New and Emerging Agents
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-and-emerging-agents/17863/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the...
03.20.2024
Quality Indicators: How Do You Compare? Part 2
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-2/17862/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the...
03.20.2024
Quality Indicators: How Do You Compare? Part 1
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-1/17861/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the...
03.20.2024
Don't Flush Another Colonoscopy Down the Toilet
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-flush-another-colonoscopy-down-the-toilet/17860/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the...
03.20.2024
Patient Education: Telling Is Not Teaching and Listening Is Not Learning
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-education-telling-is-not-teaching-and-listening-is-not-learning/17859/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the...
03.20.2024
Another Inadequate Bowel Prep? It May Not Be the Patient's Fault
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/another-inadequate-bowel-prep-it-may-not-be-the-patients-fault/17858/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the...

What's ReachMD CME about?

Download our free app to listen on your phone

ReachMD CME episodes:

Advancing the Treatment of ATTRv-PN: What's in the Pipeline?

ATTRv-PN: A Family Affair?

Shh…Gene-Silencing Therapies for ATTRv-PN

Diagnosing ATTRv-PN: What's in Your Toolbox?

Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?

The Multiple Faces of ATTRv-PN

ATTRv-PN: A Complicated Disease With a Poor Prognosis

ATTR Amyloidosis: Familial Vs Wild-Type

GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events

Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying

Duchenne Muscular Dystrophy: Differentiating Advances in Treatment

GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data

South Asians With IBD: Underrepresented and Underappreciated

How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?

Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE

VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?

Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?

Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Patient With VTE

Case Time! VTE Prophylaxis Post Hip Replacement

Right from the Onset: PE Diagnosis, Management

Right from the Onset: DVT Diagnosis, Management

What Do the Guidelines Suggest for Prophylaxis, and How Do We Implement?

Case Time! V.T. Edwards: Management of Extended Thromboprophylaxis in the Medically Ill

What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?

What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?

From Awareness to Action: What To Do With a Positive OSA Screen?

How to Screen for OSA

Overcoming Hurdles: Effective OSA Screening in Primary Care

Pre-Operative Vigilance: The Role of OSA Screening in Surgical Safety

OSA: Exploring the Impact on Morbidity and Mortality

Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma

Extending Treatment Durability With Next-Generation Neovascular AMD Therapies

Collaboration and Management of HE: Establishing Foundation for Successful Outcomes

HEar My Needs: Enhancing the Patient and Provider Dialogue

Equitable HEalth for All: Improving Care for Underserved Populations and Their Unmet Needs

How Do I Prevent Future Hospital Visits due to HE?

The Unmet Need for HE Therapy in the African American Community – Why Is This a Concern?

HElp! AASLD Guidelines Related to Diagnosis of HE

West HavEn Criteria—Meaningfulness Into Clinical Practice

Tackling the Unmet Need HEad On—What Does HE Look Like?

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Therapeutic Options for ADH1 and Hypoparathyroidism

CASR and ADH1: Integrating Biology and Genetic Screening

Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism

New and Emerging Agents

Quality Indicators: How Do You Compare? Part 2

Quality Indicators: How Do You Compare? Part 1

Don't Flush Another Colonoscopy Down the Toilet

Patient Education: Telling Is Not Teaching and Listening Is Not Learning

Another Inadequate Bowel Prep? It May Not Be the Patient's Fault